Trial Profile

Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DB 1312 (Primary) ; Tislelizumab (Primary)
Indications Advanced breast cancer; Cholangiocarcinoma; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors BeOne Medicines

Most Recent Events

06 May 2026 According to a BeOne Medicines Media Release, company received acceptance of Phase 1 study data as a rapid oral presentation at ASCO.
28 Nov 2025 Planned number of patients changed from 227 to 308.
02 Jun 2025 According to a BeOne Medicines Media Release, initial results from this trial has been presented in the ASCO 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com